pharma · Colitis, Ulcerative · Multiple Myeloma
Janssen Cilag International
Janssen Cilag International NV
Janssen-Cilag Farmaceutica Ltda is a pharma organization headquartered in São Paulo, EU. Primary therapeutic focus areas include Colitis, Ulcerative, Multiple Myeloma, Diabetes Mellitus, Type 2, Depressive Disorder, Majo
São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- São Paulo, EU
- Employees
- 13
- Programs
- 46
- Drugs
- 37
- Patents
- 0
Erdafitinib Intravesical Delivery System
Phase 2 · small molecule · Non-Muscle Invasive Bladder Neoplasms
Erdafitinib Intravesical Delivery System for Non-Muscle Invasive Bladder Neoplasms is a Phase 2 program (small_molecule) at Janssen Cilag International NV with 1 ClinicalTrials.gov record(s).
Internal code CR109115
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Janssen Cilag International NV
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Non-Muscle Invasive Bladder Neoplasms
- Status
- active
- Trials
- 1